PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
Megadott ok: For business reasons
A legfontosabb adatok
- Hol
- Albuquerque, Austin, Boca Raton, Franklin, Hollywood, Houston, Huntington Beach, Irvine, Jacksonville, Lynchburg, Miami, Miramar, Norfolk, Orlando, Oviedo, Raleigh, Skokie, St Louis, Stony Brook és Tampa (Egyesült Államok)Mind a 23 helyszín megnézése
- Fázis
- 2. fázis
Helyszínek itt: Egyesült Államok
- University of New Mexico Clinical & Translational Sciences CenterAlbuquerque, Egyesült ÁllamokNo longer taking part
- University of New Mexico Department of DermatologyAlbuquerque, Egyesült ÁllamokNo longer taking part
- Tekton Research, IncAustin, Egyesült ÁllamokNo longer taking part
- Skin Care Research, LLCBoca Raton, Egyesült ÁllamokNo longer taking part
- Summit Clinical Research, LLCFranklin, Egyesült ÁllamokNo longer taking part
- Skin Care Research, LlcHollywood, Egyesült ÁllamokNo longer taking part
- Center for Clinical Studies, LTD. LLPHouston, Egyesült ÁllamokNo longer taking part
- Marvel Clinical Research 002, LLCHuntington Beach, Egyesült ÁllamokNo longer taking part
- University of California, IrvineIrvine, Egyesült ÁllamokNo longer taking part
- Clinical NeuroScience Solutions IncJacksonville, Egyesült ÁllamokNo longer taking part
- Kendall Adkisson, MD - Intracoastal DermatologyJacksonville, Egyesült ÁllamokNo longer taking part
- The Education & Research Foundation, Inc.Lynchburg, Egyesült ÁllamokNo longer taking part
- Y&L Advance Health Care, Inc d/b/a Elite Clinical ResearchMiami, Egyesült ÁllamokNo longer taking part
- BRCR Medical Center IncMiramar, Egyesült ÁllamokNo longer taking part
- Virginia Dermatology and Skin Cancer CenterNorfolk, Egyesült ÁllamokNo longer taking part
- Clinical Neuroscience Solutions Inc. dba CNS HealthcareOrlando, Egyesült ÁllamokNo longer taking part
- Orlando Dermatology & Skin Cancer Surgery CenterOviedo, Egyesült ÁllamokNo longer taking part
- M3 Wake Research, Inc.Raleigh, Egyesült ÁllamokNo longer taking part
- NorthShore University HealthSystem Dermatology ClinicSkokie, Egyesült ÁllamokNo longer taking part
- NorthShore University HealthSystem Dermatology Clinical Trials UnitSkokie, Egyesült ÁllamokNo longer taking part
- Washington University School of Medicine DermatologySt Louis, Egyesült ÁllamokNo longer taking part
- Stony Brook DermatologyStony Brook, Egyesült ÁllamokNo longer taking part
- USF Health Morsani Center for Advanced HealthcareTampa, Egyesült ÁllamokNo longer taking part
A vizsgálat adatai
- Ki végzi
- Pfizer
- Azonosító
- NCT04517864
- A regiszteradat frissítve
- 2025. július 11.
- Eredeti leírás
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).A teljes eredeti leírásKevesebb
A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
Bevonási feltételek: Diagnosis of alopecia areata, including alopecia totalis and alopecia universalis; At least 25% hair loss due to alopecia areata; Must have normal hearing and normal brainstem auditory evoked potentials (BAEPs); Must have a normal neurological exam; can have a stable unilateral median neuropathy or ulnar neuropathy; Signed informed consent; Stable regimen for other medications before and during the study.
Kizáró feltételek: Concomitant medications associated with peripheral neurologic or hearing loss; Other significant medical conditions; History of peripheral neuropathy or first degree relative with a hereditary peripheral neuropathy; Active or chronic infection; or infection requiring hospitalization or IV antimicrobials within 6 months; Active or latent (insufficiently treated) Hepatitis; HbA1c > or = 7.5% at Screening; Protocol specific laboratory abnormalities; Occupational or recreational noise exposure; Recurrent or disseminated Herpes Zoster; Active or latent (insufficiently treated) TB.